Skip to content
DataLookout
Menu

OLYMPIA-4NCT06230224

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 37 versions: 36 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words Show 4 more changesShow less
    • Study completion moved earlier from May 29, 2029 to May 29, 2028
    • Secondary endpoints: 22 to 21
    • Primary endpoint revised
    • Site details revised at 7 of 81 sites
  2. Notable Primary completion pushed from May 14, 2027 to May 29, 2028
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Trial sites reduced: 101 → 81 locations
    • Study completion pushed from May 14, 2027 to May 29, 2029
    v36
  3. Minor Study sites: 99 to 101v35
  4. Minor Study sites: 98 to 99v34
  5. Minor Study sites: 96 to 98v33
Show 30 earlier versionsHide 30 earlier versions
  1. Minor Study sites: 92 to 96v32
  2. Minor Study sites: 91 to 92v31
  3. Minor Study sites: 87 to 91v30
  4. Minor Study sites: 86 to 87v29
  5. Minor Study sites: 85 to 86v28
  6. Minor Study sites: 83 to 85v27
  7. Minor Study sites: 81 to 83v26
  8. Minor Study sites: 80 to 81v25
  9. Minor Study sites: 76 to 80v24
  10. Notable Primary endpoint revised
    • Study sites: 62 to 76
    • Secondary endpoints: 23 to 22
    v22
  11. Minor Study sites: 61 to 62v21
  12. Minor Study sites revised (61)v20
  13. Minor Site details revised at 3 of 61 sitesv19
  14. Minor Site details revised at 6 of 61 sitesv18
  15. Minor Study sites: 60 to 61v17
  16. Minor Study sites: 58 to 60v16
  17. Minor Study sites: 56 to 58v15
  18. Minor Study sites: 55 to 56v14
  19. Minor Study sites: 53 to 55v13
  20. Notable Eligibility criteria expanded, about 16 words
    • Primary and study completion dates: Jul 6, 2027 to May 14, 2027
    • Secondary endpoints revised (23)
    • Study sites revised (53)
    v12
  21. Minor Study sites: 51 to 53v11
  22. Minor Study sites: 49 to 51v10
  23. Minor Study sites: 42 to 49v9
  24. Minor Study sites: 39 to 42v8
  25. Minor Study sites: 30 to 39v7
  26. Minor Study sites: 18 to 30v6
  27. Minor Study sites: 17 to 18v5
  28. Minor Study sites: 15 to 17v4
  29. Minor Study sites: 10 to 15
    • Start date changed from estimate of Feb 5, 2024 to Feb 15, 2024
    v3
  30. Minor Study sites: 1 to 10v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Event-Free Survival (EFS) as assessed by independent central review (ICR)
Timeframe: Assessed up to 3 years

Secondary (21)

Progression Free Survival (PFS) as assessed by ICR
Best Overall Response (BOR) as assessed by ICR
Overall Survival (OS)
Overall change in physical functioning as measured by scores of the physical function scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30)
EFS as assessed by local investigator
Show 16 moreShow less
PFS as assessed by local investigator
BOR as assessed by local investigator
Complete Response (CR) as assessed by ICR
CR as assessed by local investigator
Duration of response (DOR) assessed by ICR
DOR assessed by local investigator
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Odronextamab concentrations in serum
Occurrence of Anti-Drug Antibodies (ADAs) to odronextamab
Magnitude of ADAs to odronextamab
Measurable Residual Disease (MRD) status
Overall change in Patient-Reported Outcomes (PROs), as measured by scores of the EORTCQLQ- C30
Overall change in PROs, as measured by scores of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-LymS)
Overall change in PROs, as measured by scores of the EuroQol-5 Dimension-5 Level Scale (EQ-5D-5L)
Overall change in score of the Global Population item 5 (GP5) of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire

Arms and interventions

OdronextamabExperimental

Participants will receive odronextamab monotherapy.

Standard Of CareActive comparator

Participants will receive salvage therapy (ifosfamide, carboplatin, etoposide ± rituximab \[ICE ± R\], or dexamethasone, cisplatin, cytarabine ± rituximab \[DHAP ± R\], or gemcitabine, dexamethasone, cisplatin ± rituximab \[GDP ± R\]) and continue with autologous stem cell transplant (ASCT) following a complete response (CR)/partial response (PR).

Drugs: Odronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab, Dexamethasone, Cisplatin, Cytarabine, Gemcitabine

Sites

81 sites in 14 countries

Brazil 15, South Korea 12, Turkey (Türkiye) 11, Argentina 9, Taiwan 9, Malaysia 5, Spain 4, Thailand 4, Hungary 3, Australia 2, Chile 2, Colombia 2, Romania 2, Singapore 1